Nimodipine in Clinical Practice: A Pharmacological Update

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Medicine

Background:

• Nimodipine is the sole FDA-approved medication for aneurysmal subarachnoid hemorrhage (aSAH).
• Optimal dosing and patient-specific variables influencing nimodipine tolerability remain under-investigated.
• The clinical impact of altering nimodipine dosage or frequency, particularly concerning hypotension risk, is debated.

Purpose of the Study:

• To review factors influencing enteral nimodipine dosing and administration in aSAH patients.
• To explore pharmacokinetic and pharmacogenetic considerations for nimodipine therapy.
• To identify potential drug interactions relevant to nimodipine treatment in aSAH.

Main Methods:

• Literature review of studies on nimodipine in aSAH.
• Analysis of pharmacokinetic and pharmacogenetic data.
• Examination of drug interaction profiles.

Main Results:

• Dosing and administration require careful consideration of patient-specific variables.
• Pharmacokinetic and pharmacogenetic factors can significantly impact nimodipine efficacy and tolerability.
• Potential drug interactions necessitate thorough assessment during nimodipine initiation.

Conclusions:

• Optimizing nimodipine therapy involves understanding individual patient factors and potential interactions.
• Further research into personalized nimodipine dosing strategies is warranted.
• This review provides a framework for informed clinical decision-making regarding nimodipine use in aSAH.